FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels
Pharma & biotech2018-06-20
17 Views
The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Regeneron Pharmaceuticals' (Nasdaq: REGN) REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
